Work

161P First-line PD-1 inhibitor toripalimab plus chemotherapy for patients with advanced thymic epithelial tumors: A prospective, single-arm, phase II trial

Year: 2025

Type: article

Abstract: Thymic carcinomas (TCs) and invasive thymoma are aggressive subtypes of thymic epithelial tumors. Chemotherapy is the standard treatment for advanced TCs, although achieved a response less than 50%. Immunotherapy has been crucial in the treatment of several malignancies. Here we conducted a phase II, prospective trial to explore the safety and feasibility of toripalimab (a PD-1 inhibitor) plus chemotherapy as first-line treatment in advanced TCs.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104476

Author: K. Zhu

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910